Principal Financial Group Inc. Acquires 18,863 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Principal Financial Group Inc. increased its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 596,590 shares of the biopharmaceutical company’s stock after purchasing an additional 18,863 shares during the quarter. Principal Financial Group Inc. owned approximately 0.45% of Dynavax Technologies worth $7,618,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mizuho Markets Americas LLC raised its stake in shares of Dynavax Technologies by 17.4% in the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after buying an additional 204,475 shares during the period. Bank of Montreal Can increased its holdings in Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after acquiring an additional 82,449 shares in the last quarter. Nordea Investment Management AB raised its stake in Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after acquiring an additional 232,690 shares during the period. PDT Partners LLC purchased a new position in Dynavax Technologies during the third quarter valued at approximately $3,967,000. Finally, Rhumbline Advisers lifted its holdings in Dynavax Technologies by 4.7% during the fourth quarter. Rhumbline Advisers now owns 305,718 shares of the biopharmaceutical company’s stock valued at $3,904,000 after purchasing an additional 13,597 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $15.00 to $12.00 in a research report on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Finally, William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $13.79 on Friday. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 76.61 and a beta of 1.32. The firm has a fifty day moving average price of $12.89 and a 200 day moving average price of $12.11. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.05. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, sell-side analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.